NUFORMIX PLC

Board/Management Information • Feb 5, 2020

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1161C

Nuformix PLC

05 February 2020

5 February 2020

Nuformix plc

("Nuformix" or "the Group"),

Resignation of Dave Tapolczay

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs announces the resignation of Dave Tapolczay as non-executive Chairman of the Nuformix Board of Directors with immediate effect.

Dr Dan Gooding, CEO, Nuformix plc, said: "Following Dave's resignation, Dr Chris Blackwell will undertake the role of interim Chairman. Dave's departure creates an opportunity to bring new specialist life sciences experience to the Board, at a time when Nuformix faces exciting opportunities to continue its trajectory of progress and we look forward to updating shareholders on developments with both the Company and the Board in the near future"

Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.

Enquiries:

Nuformix plc Dr Dan Gooding, Chief Executive Officer Email: info@nuformix.com	+44 (0)1223 627222
Novum Securities Limited Jon Belliss / Colin Rowbury	+44 (0)20 7399 9427

About Nuformix plc www.nuformix.com 

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2009 and has invested in pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. 

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOAUVSNRROUURAR